Literature DB >> 19296240

18F-FDG-PET imaging of a benign neurofibroma masquerading as metastatic oesophageal carcinoma.

A Azad1, G Chong, A Tauro, A Aly, N C Tebbutt.   

Abstract

We present the case of a 65-year-old male with squamous cell carcinoma of the thoracic oesophagus on a background of neurofibromatosis type 1. On computed tomography, he was noted to have a large left-sided superior mediastinal mass. Initially, this mass was thought to be metastatic lymphadenopathy; however, it did not display fluorodeoxyglucose uptake on positron emission tomography. Subsequent biopsy confirmed the mass to be a neurofibroma and the patient commenced definitive chemo-radiation. Positron emission tomography had a major impact on management since the presumed lymph node disease was not included in the radiation field. In addition, positron emission tomography altered prognostic stratification since lymph node involvement is a poor prognostic factor in oesophageal cancer. We could only identify one other case in the English literature in which positron emission tomography was used to distinguish metastatic carcinoma from a neurofibroma, although there are a number of reports that describe the utility of positron emission tomography in differentiating benign neurofibromas from malignant connective tissue tumours.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19296240     DOI: 10.1007/s12032-009-9196-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  9 in total

Review 1.  Esophageal cancer.

Authors:  Peter C Enzinger; Robert J Mayer
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

2.  Prevalence of neurofibromatosis 1 in German children at elementary school enrollment.

Authors:  Marga Lammert; Jan M Friedman; Lan Kluwe; Victor F Mautner
Journal:  Arch Dermatol       Date:  2005-01

3.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.

Authors:  J S Cooper; M D Guo; A Herskovic; J S Macdonald; J A Martenson; M Al-Sarraf; R Byhardt; A H Russell; J J Beitler; S Spencer; S O Asbell; M V Graham; L L Leichman
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

4.  Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.

Authors:  R E Ferner; J D Lucas; M J O'Doherty; R A Hughes; M A Smith; B F Cronin; J Bingham
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

5.  INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.

Authors:  Bruce D Minsky; Thomas F Pajak; Robert J Ginsberg; Thomas M Pisansky; James Martenson; Ritsuko Komaki; Gordon Okawara; Seth A Rosenthal; David P Kelsen
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

6.  Neurofibroma with increased uptake of [F-18]-fluoro-2 deoxy-D-glucose interpreted as a metastatic lesion.

Authors:  Chung-Huei Hsu; Chi-Ming Lee; Fong-Chieh Wang; Chia-Lang Fang
Journal:  Ann Nucl Med       Date:  2003-10       Impact factor: 2.668

7.  Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours.

Authors:  S Cardona; M Schwarzbach; Ulf Hinz; A Dimitrakopoulou-Strauss; N Attigah; G Mechtersheimer section sign; T Lehnert
Journal:  Eur J Surg Oncol       Date:  2003-08       Impact factor: 4.424

8.  [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.

Authors:  R E Ferner; J F Golding; M Smith; E Calonje; W Jan; V Sanjayanathan; M O'Doherty
Journal:  Ann Oncol       Date:  2007-10-11       Impact factor: 32.976

9.  A prospective study of neurofibromatosis type 1 cancer incidence in the UK.

Authors:  L Walker; D Thompson; D Easton; B Ponder; M Ponder; I Frayling; D Baralle
Journal:  Br J Cancer       Date:  2006-06-20       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.